BRAINSTORM CELL THERAPEUTICS INC.

BCLI OTC CIK: 0001137883

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 1325 AVENUE OF AMERICAS, NEW YORK, NY, 10019
Mailing Address 1325 AVENUE OF AMERICAS, NEW YORK, NY, 10019
Phone 201-488-0460
Fiscal Year End 1231
EIN 207273918

Financial Overview

FY2025

$1.83M
Total Assets
$187K
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 31, 2026 View on SEC
10-K Annual financial report March 31, 2026 View on SEC
8-K Current report of material events February 27, 2026 View on SEC
8-K Current report of material events February 13, 2026 View on SEC
8-K Current report of material events January 9, 2026 View on SEC
8-K Current report of material events November 14, 2025 View on SEC
10-Q Quarterly financial report November 14, 2025 View on SEC
8-K Current report of material events November 6, 2025 View on SEC
8-K Current report of material events August 14, 2025 View on SEC
10-Q Quarterly financial report August 14, 2025 View on SEC

Annual Reports

10-K March 31, 2026
  • FDA has formally agreed to the design of a new Phase 3b clinical trial for the NurOwn® ALS treatment.
  • The company is focused on autologous cell therapy, harvesting patient stem cells to repair nerve tissue.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.